Crescent Biopharma, Inc.
CBIOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Crescent Biopharma, Inc. (CBIO) is listed under Biotechnology. At a $476.2M market cap, Crescent Biopharma, Inc. ranks as a small-cap company within healthcare. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Market Cap
$476.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.87
EPS (TTM)
$-7.63
EPS (Fwd)
$-2.63
ROE
—
ROA
—
Cash
$171.6M
Total Debt
$1.4M
Free CF
—
52W Change
1.0%
Annual Financials
Cash vs Debt
Where CBIO stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CBIO finished 31.64% below its 150-day moving average ($17.32) and 25.02% below its 200-day moving average ($15.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBIO overbought or oversold?
At the October 19, 2026 close, CBIO's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $171.6M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing CBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.